Osaic Holdings’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Osaic Holdings’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,200	Closed	-$129K	–	7660
2023 Q1	$129K	Sell	1,200 -211	-15%	-$24.3K	﹤0.01%	4227
2022 Q4	$155K	Sell	1,411 -727	-34%	-$47.1K	﹤0.01%	4083
2022 Q3	$126K	Buy	2,138 +1,849	+640%	+$84.6K	﹤0.01%	4165
2022 Q2	$8K	Buy	289 +94	+48%	+$2.73K	﹤0.01%	6270
2022 Q1	$7K	Hold	195	–	–	﹤0.01%	6362
2021 Q4	$8K	Buy	+195	New	+$6.1K	﹤0.01%	6432

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Osaic Holdings's RXDX Position: Q2 2023 in Review

Osaic Holdings sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,200 shares — an estimated $129K sold.

Osaic Holdings first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $155K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Osaic Holdings reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Osaic Holdings sold 1,200 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $129K.
Osaic Holdings first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Osaic Holdings's Prometheus Biosciences, Inc. Common Stock position peaked at $155K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Osaic Holdings's 13F filing for Q2 2023, filed 10 Aug 2023.